Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Inclusion Criteria:

- Subject must have a documented diagnosis of ocular hypertension, open angle glaucoma
(with or without pseudoexfoliation or pigment dispersion component).

- Subject has a mean baseline IOP following washout in at least 1 eye (the same eye) of

≥ 24mmHg at Hour 0 (T0) at Baseline Visit 1 and Baseline Visit 2 (Day 1)

- Subject has a mean baseline IOP following washout in at least 1 eye (the same eye)
of:

≥ 22mmHg at (T0 + 4h) and (T0 + 8h) at Baseline Visit 1 (note: the same eye must meet
the IOP eligibility criteria at all 4 baseline assessments)

- Washout IOP must be ≤ 34mmHg in each eye at all time points at the Baseline Visit 1
and Baseline Visit 2 (Day 1)

Exclusion Criteria:

- Subject with any form of glaucoma other than open angle glaucoma (with or without a
pigment dispersion or pseudoexfoliation component).

- Subject with mean baseline IOP >34 mmHg in either eye at any time point during the
Baseline Visits 1 or 2 (Day 1).

- Subject with a BCVA worse than 0.6 logMAR (20/80 Snellen) in either eye as measured
using an ETDRS chart.

- Subject with a known or suspected allergy and/or hypersensitivity to travoprost,
timolol, fluorescein or to any component of the study products.